Runxia Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Runxia Gu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiang Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
14 shared publications - Shaowei Qiu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 shared publications - Min Wang
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications - Qing Rao
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
10 shared publications - Yihan Mei
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
9 shared publications - Fan Ding
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72395
Transcriptome Analysis Identifies a Myeloid‐Like Signature in Relapsed or Refractory B ‐Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy
Background: Relapsed or refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) patients exhibit heterogeneous responses to CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy. However, current studies primarily focus on the CAR‐T cells or the leukemia blasts, and the patient's intrinsic molecular characteristics before treatment remain poorly understood. Methods: Fifteen R/R B‐ALL patients enrolled in a phase II, single‐arm clinical trial (NCT04684147) were stratified at a three‐month landmark into 8 good responders and 7 poor responders. Clinical characteristics, genetic alterations and pre‐treatment bone marrow transcriptomics were compared between groups, and an exploratory gene‐expression score was derived. Results: Differential expression and enrichment analyses identified a myeloid‐like signature and upregulation of myeloid‐related genes in poor responders. Seven myeloid‐related genes were examined in independent patient cohorts, in B‐ALL cell lines and at single‐cell resolution in one patient; three were expressed by the leukemic cells themselves and four predominantly by monocytes and macrophages. A separate, variance‐derived seven‐gene least absolute shrinkage and selection operator (LASSO) score separated response groups in the discovery cohort (apparent area under the curve, AUC 1.00), with bias‐corrected and external estimates of approximately 0.57–0.59 (external cohort AUC 0.592, 95% confidence interval 0.356–0.828). Conclusions: Pre‐treatment transcriptomic profiling revealed a myeloid‐like signature in R/R B‐ALL patients with poor CD19 CAR‐T response, warranting further investigation as a candidate correlate of treatment outcome.
- 19 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72395
Open AccessTranscriptome Analysis Identifies a Myeloid‐Like Signature in Relapsed or Refractory B ‐Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy
Background: Relapsed or refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) patients exhibit heterogeneous responses to CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy. However, current studies primarily focus on the CAR‐T cells or the leukemia blasts, and the patient's intrinsic molecular characteristics before treatment remain poorly understood. Methods: Fifteen R/R B‐ALL patients enrolled in a phase II, single‐arm clinical trial (NCT04684147) were stratified at a three‐month landmark into 8 good responders and 7 poor responders. Clinical characteristics, genetic alterations and pre‐treatment bone marrow transcriptomics were compared between groups, and an exploratory gene‐expression score was derived. Results: Differential expression and enrichment analyses identified a myeloid‐like signature and upregulation of myeloid‐related genes in poor responders. Seven myeloid‐related genes were examined in independent patient cohorts, in B‐ALL cell lines and at single‐cell resolution in one patient; three were expressed by the leukemic cells themselves and four predominantly by monocytes and macrophages. A separate, variance‐derived seven‐gene least absolute shrinkage and selection operator (LASSO) score separated response groups in the discovery cohort (apparent area under the curve, AUC 1.00), with bias‐corrected and external estimates of approximately 0.57–0.59 (external cohort AUC 0.592, 95% confidence interval 0.356–0.828). Conclusions: Pre‐treatment transcriptomic profiling revealed a myeloid‐like signature in R/R B‐ALL patients with poor CD19 CAR‐T response, warranting further investigation as a candidate correlate of treatment outcome.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- Open Access
- 21 May 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (13) , 1670-1682
Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia
The BCL-2 inhibitor venetoclax has shown promise in acute lymphoblastic leukemia (ALL), but its role in first-line therapy for newly diagnosed (ND) Philadelphia chromosome-negative (Ph⁻) ALL is undefined. In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph⁻ ALL received venetoclax combined with pediatric-inspired chemotherapy. The primary endpoint was the rate of measurable residual disease (MRD) negativity by multiparameter flow cytometry (MFC) after induction. The complete remission rate was 91.0%, and 73.0% of responders achieved MFC-MRD negativity, meeting the primary endpoint. After a median follow-up of 19.3 months, median overall and disease-free survival were not reached; estimated 2-year survival rates were 78.5% and 76.7%, respectively. Propensity score-matched analysis confirmed superior survival compared with historical chemotherapy-only controls. Grade ≥ 3 adverse events were primarily hematologic toxicities and infections, with an incidence comparable to that of the historical cohort. These results demonstrate that adding venetoclax to pediatric-inspired chemotherapy significantly improves MRD response and survival outcomes in ND Ph⁻ ALL, with a manageable safety profile. This trial was registered with ClinicalTrials.gov under the identifier NCT05660473.
- 21 May 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (13) , 1670-1682
Open AccessVenetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia
The BCL-2 inhibitor venetoclax has shown promise in acute lymphoblastic leukemia (ALL), but its role in first-line therapy for newly diagnosed (ND) Philadelphia chromosome-negative (Ph⁻) ALL is undefined. In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph⁻ ALL received venetoclax combined with pediatric-inspired chemotherapy. The primary endpoint was the rate of measurable residual disease (MRD) negativity by multiparameter flow cytometry (MFC) after induction. The complete remission rate was 91.0%, and 73.0% of responders achieved MFC-MRD negativity, meeting the primary endpoint. After a median follow-up of 19.3 months, median overall and disease-free survival were not reached; estimated 2-year survival rates were 78.5% and 76.7%, respectively. Propensity score-matched analysis confirmed superior survival compared with historical chemotherapy-only controls. Grade ≥ 3 adverse events were primarily hematologic toxicities and infections, with an incidence comparable to that of the historical cohort. These results demonstrate that adding venetoclax to pediatric-inspired chemotherapy significantly improves MRD response and survival outcomes in ND Ph⁻ ALL, with a manageable safety profile. This trial was registered with ClinicalTrials.gov under the identifier NCT05660473.
- Open Access
- 5 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (10) , 2573
Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
- 5 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (10) , 2573
Open AccessCorrection: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
- 30 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (8) , 1838-1847
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
Tyrosine kinase inhibitors (TKIs) combined with chemotherapy and immunotherapy evolved as the standard treatment for newly diagnosed (ND) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nonetheless, the efficacy and safety of combining TKIs with BCL-2 inhibitors in ND Ph+ ALL have yet to be fully elucidated. Hence, we carried out a prospective clinical trial to explore the efficacy and safety of olverembatinib combined with venetoclax and reduced-intensity chemotherapy as frontline treatment in Ph+ ALL. From October 2022 to March 2024, a total of 79 patients with a median age of 42 years completed a minimum of three cycles of olverembatinib and venetoclax-based regimen. The primary end point of the study was the complete molecular response (CMR) rate at 3 months. Ultimately, the regimen achieved CMR of 62.0% at 3 months in the absence of intensive chemotherapy or immunotherapy. No deaths occurred during the induction phase. With a median follow-up of 12 months, the estimated 1-year overall survival (OS) and event-free survival (EFS) rates were 93.1% (95% CI 86.4–99.8) and 89.1% (95% CI 80.3–97.9), respectively. Transcriptomic data revealed a potential complementary mechanism between TKIs and venetoclax, thereby verifying the rationale for the combination of these two agents. In conclusion, our study provides an alternative treatment strategy for patients with ND Ph+ ALL, particularly for those who are unfit or unavailable for immunotherapy or intensive chemotherapy at the initial stage of treatment. Clinical trial registration: The study was registered at https://clinicaltrials.gov/ with the registration number of NCT05594784.
- 30 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (8) , 1838-1847
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
Tyrosine kinase inhibitors (TKIs) combined with chemotherapy and immunotherapy evolved as the standard treatment for newly diagnosed (ND) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nonetheless, the efficacy and safety of combining TKIs with BCL-2 inhibitors in ND Ph+ ALL have yet to be fully elucidated. Hence, we carried out a prospective clinical trial to explore the efficacy and safety of olverembatinib combined with venetoclax and reduced-intensity chemotherapy as frontline treatment in Ph+ ALL. From October 2022 to March 2024, a total of 79 patients with a median age of 42 years completed a minimum of three cycles of olverembatinib and venetoclax-based regimen. The primary end point of the study was the complete molecular response (CMR) rate at 3 months. Ultimately, the regimen achieved CMR of 62.0% at 3 months in the absence of intensive chemotherapy or immunotherapy. No deaths occurred during the induction phase. With a median follow-up of 12 months, the estimated 1-year overall survival (OS) and event-free survival (EFS) rates were 93.1% (95% CI 86.4–99.8) and 89.1% (95% CI 80.3–97.9), respectively. Transcriptomic data revealed a potential complementary mechanism between TKIs and venetoclax, thereby verifying the rationale for the combination of these two agents. In conclusion, our study provides an alternative treatment strategy for patients with ND Ph+ ALL, particularly for those who are unfit or unavailable for immunotherapy or intensive chemotherapy at the initial stage of treatment. Clinical trial registration: The study was registered at https://clinicaltrials.gov/ with the registration number of NCT05594784.
- Top Cited PapersOpen Access
- 14 February 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (4) , 836-843
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Before November 2023, CD19 chimeric antigen receptor (CAR) T-cell therapies had not been approved in China for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), leaving a significant unmet need. In response, inaticabtagene autoleucel (Inati-cel), a novel CD19 CAR T-cell therapy with a distinct single-chain variable fragment (HI19α), was developed and showed promising efficacy in preliminary clinical research. We conducted a phase 2, single-arm, multicenter study of Inati-cel in adult CD19+ R/R B-ALL in China. The primary end point was the overall remission rate (ORR) at the end of month 3. Forty-eight patients who underwent Inati-cel infusion were evaluated for both efficacy and safety. Among them, 34 patients achieved and maintained remission beyond 3 months, with a 3-month ORR of 70.8% (95% confidence interval [CI], 55.9-83.1). The best ORR was 85.4%, with all responders reaching minimal residual disease negativity. With a median follow-up of 23.7 months, the median duration of remission was 20.7 months (95% CI, 6.4 to not reached), and the median overall survival was not reached (95% CI, 13.0 months to not reached). Additionally, grade ≥3 cytokine release syndrome and neurologic events occurred in 12.5% and 6.2% of patients, respectively. The 2-year follow-up data suggest that Inati-cel demonstrates encouraging and durable responses with manageable safety profiles in R/R B-ALL. Based on the data from this pivotal trial, Inati-cel was approved as the first CAR T-cell therapy for adult R/R B-ALL in China and underscores its potential therapeutic benefits for this patient population. This trial was registered at www.ClinicalTrials.gov as #NCT04684147.
- 14 February 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (4) , 836-843
Top Cited PapersOpen AccessInaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Before November 2023, CD19 chimeric antigen receptor (CAR) T-cell therapies had not been approved in China for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), leaving a significant unmet need. In response, inaticabtagene autoleucel (Inati-cel), a novel CD19 CAR T-cell therapy with a distinct single-chain variable fragment (HI19α), was developed and showed promising efficacy in preliminary clinical research. We conducted a phase 2, single-arm, multicenter study of Inati-cel in adult CD19+ R/R B-ALL in China. The primary end point was the overall remission rate (ORR) at the end of month 3. Forty-eight patients who underwent Inati-cel infusion were evaluated for both efficacy and safety. Among them, 34 patients achieved and maintained remission beyond 3 months, with a 3-month ORR of 70.8% (95% confidence interval [CI], 55.9-83.1). The best ORR was 85.4%, with all responders reaching minimal residual disease negativity. With a median follow-up of 23.7 months, the median duration of remission was 20.7 months (95% CI, 6.4 to not reached), and the median overall survival was not reached (95% CI, 13.0 months to not reached). Additionally, grade ≥3 cytokine release syndrome and neurologic events occurred in 12.5% and 6.2% of patients, respectively. The 2-year follow-up data suggest that Inati-cel demonstrates encouraging and durable responses with manageable safety profiles in R/R B-ALL. Based on the data from this pivotal trial, Inati-cel was approved as the first CAR T-cell therapy for adult R/R B-ALL in China and underscores its potential therapeutic benefits for this patient population. This trial was registered at www.ClinicalTrials.gov as #NCT04684147.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends